Makers of single-use medical supplies — the things used once and thrown away, like syringes, bandages, surgical gloves and test kits.
Contains
News movingHealth Care Supplies
Health Care Supplies▲
Jana Partners Urges Cooper Companies to Replace CEO and Explore Sale
Activist investor Jana Partners has sent a letter to Cooper Companies urging the contact lens maker to pursue a sale and change its leadership, according to a Wall Street Journal report. Jana said Cooper requires an urgent overhaul to address what it called chronic underperformance and its inability to manage inventory and capital spending. The hedge fund called on the company to replace CEO Albert White, appoint a new board chair, engage with potential buyers of the contact lens business, and consider selling its fertility and medical device assets. Jana began building its stake in Cooper roughly a year ago and previously suggested the company consider strategic alternatives, including a potential combination with rival Bausch + Lomb. Cooper shares climbed 1.7% post-market Thursday on the report; they have slumped 34% year to date, and the company reduced its full-year outlook earlier this month after lowering its contact lens inventory as part of a strategic review.
BofA Upgrades Haemonetics to Buy on New CSL Supply Deal
Bank of America upgraded Haemonetics to Buy from Neutral on Thursday, citing a recent supply deal the blood management solutions provider signed with Australian biopharma company CSL Limited. The non-exclusive deal follows CSL's decision to terminate its plasma supply agreement with Haemonetics in 2021 and carries no minimum purchase requirements, BofA analyst Joanne Wuensch wrote. Wuensch said that in a healthy plasma market, the return of the CSL contract in the US market should provide upside to organic revenue growth, operating margins, and EPS over the next several years, and she raised her price target on Haemonetics to $123 from $92 per share. Haemonetics, based in Boston, Massachusetts, disclosed the deal last month and said it will report the financial impact on fiscal 2027 results alongside its fiscal second-quarter earnings, scheduled for November.
Cooper Companies Cuts Fiscal 2026 Guidance as Contact Lens Demand Slows
The Cooper Companies cut its fiscal 2026 profit and revenue forecasts after weaker-than-expected demand for contact lenses weighed on its CooperVision business. The company now expects adjusted earnings of $4.51 to $4.55 per share, down from its previous forecast of $4.58 to $4.66, while revenue guidance was reduced to $4.23 to $4.25 billion from $4.29 to $4.32 billion. Third-quarter revenue came in at $1.07 billion, below Wall Street's $1.10 billion estimate, although adjusted EPS of $1.15 beat expectations. The weakness was concentrated in CooperVision, where revenue fell to $717 million, and Cooper said a reduction in U.S. channel inventory hurt results and is expected to continue affecting the fourth quarter. The company also completed its strategic review and decided to retain CooperSurgical rather than sell the business, disappointing investors, while increasing its share-repurchase authorization from $2 billion to $3 billion.
STAAR Surgical Swings to Profit as China Sales More Than Double
STAAR Surgical reported second-quarter results on August 12 for the quarter ended July 3, swinging to $8.1 million of net income from a year-earlier loss as net sales jumped 111% year over year to $93.5 million. China sales more than doubled to $52.3 million, now accounting for more than half of total revenue, driven largely by the EVO+ lens variant launched earlier in the year, which lifted both procedure volumes and average selling prices as patients shifted toward pricier toric lenses. Sales outside China rose 6% to $41.2 million, with the Americas up 12% on growing US market share and EMEA excluding the Middle East also up 12%, while overall EMEA slipped 1% on continued Middle East disruption. Gross margin improved to 74.5% from 74.0%, and the company ended the quarter with $181.5 million in cash and no debt, up from $163.9 million three months earlier. Management cautioned that the 111% growth reflects an unusually weak year-earlier baseline, when STAAR shipped only minimal quantities to China as distributors worked down excess inventory, and asked investors to compare the coming third quarter against an adjusted base of $68.8 million rather than the reported $94.7 million, which included a one-time $25.9 million order. New CEO Warren Foust, who became permanent CEO after six months as interim co-CEO, is still searching for a Chief Technology Officer to lead the promised innovation push.
UnitedHealth sells Optum Florida stake to TPG as CooperCompanies cuts guidance and Amgen slides
UnitedHealth has sold an interest in some of its Optum Health operations in Florida to private equity firm TPG, part of the health conglomerate's effort to recover from a collapse in profits last year. CFO Wayne DeVeydt told Bloomberg News that Optum Health margins will be around 2% this year, above prior expectations, and should rise to around 4% in 2027 and 6% the following year. Amgen fell more than 8%, its worst single-day decline since 2016, after Novartis announced a Phase 3 trial failure for the heart disease therapy pelacarsen, which it is developing with Ionis Pharmaceuticals; BMO Capital Markets downgraded Amgen to Market Perform from Market Outperform with a $450 price target. CooperCompanies dropped 13% after issuing fiscal 2026 guidance below consensus, with revenue of $4.229B-$4.252B versus the prior $4.285B-$4.321B and non-GAAP diluted EPS of $4.51-$4.55 versus $4.58-$4.66 previously, and said its board decided to keep CooperSurgical rather than sell it while raising its share buyback authorization to $3B from $2B. Novo Nordisk fell more than 1% premarket after Morgan Stanley downgraded the stock to Underweight from Equal-weight, citing the semaglutide patent cliff, and the S&P 500 Health Care Sector Index slipped more than 3.5% for the week.
Five of Six Key S&P 500 Firms Beat EPS Estimates as Oracle and Copart Surge
Five of the six key S&P 500 companies that reported earnings this week beat consensus EPS estimates and expanded profits year over year, while all six grew revenue year over year. Oracle rose nearly 7% after hours on a Q1 beat, with adjusted EPS of $1.92 versus $1.75 consensus on $19.35B in revenue, up 30% year over year, and guided to at least $90B in FY27 revenue and adjusted EPS of $8.10. Copart reported mixed fiscal Q4 results, with revenue up 2.7% to $1.15B but GAAP EPS of $0.35 missing by $0.03, and agreed to acquire ACV Auctions for $10.50 per share in cash, sending CPRT up 10% and ACVA up 43% in extended trading. Casey's General Stores fell 14.2% despite a Q1 beat, with revenue up 24.5% to $5.69B and GAAP EPS of $7.37, while CooperCompanies slipped 14.7% after cutting FY26 revenue guidance to $4.229B–$4.252B and non-GAAP EPS to $4.51–$4.55, ending its strategic review by retaining CooperSurgical and expanding its buyback authorization to $3B. Adobe fell 2.7% after hours despite Q3 adjusted EPS of $6.13 on $6.76B in revenue and raised FY26 targets, as its Q4 revenue midpoint of $6.825B slightly missed the $6.84B consensus, and Kroger fell 2.8% premarket despite a Q2 beat with revenue of $34.6B and adjusted EPS of $1.09, after lowering its full-year identical sales growth outlook to 0.2%–0.8%.
MiniMed Posts 15.8% Revenue Jump in First Stand-Alone Quarter
MiniMed reported its first full quarter as a stand-alone public company on September 1, with revenue rising 15.8% to $843 million and management raising its full-year organic revenue growth guidance to roughly 10.5% from 10%. US revenue grew 13.1%, a sharp acceleration from the 1.5% growth posted in the prior quarter, as the MiniMed Flex insulin pump that began shipping in late June drove new US pump sales up more than 20% year over year and new prescribers writing for Flex up 24%. International revenue grew 16.9%, helped by a threefold increase in Simplera sensor manufacturing output, with new pump sales jumping 50% in the UK and 20% in France after the region gained access to the 15-day Instinct sensor. Profitability lagged the top line: adjusted EBITDA margin was 9.9% and free cash flow was negative $90 million, including $111 million in separation and standup costs, without which free cash flow would have been positive $21 million, while only 17 of 160 transition service agreements with Medtronic have been exited. MiniMed also flagged that an extra week in its fiscal calendar added 4 to 6 percentage points to the quarter's growth rate, and noted that hedge fund ownership rose from 22 funds to 26 while short interest stands at 20.66% of float.
CooperCompanies missed Wall Street's revenue expectations in Q2 CY2026, with sales flat year on year at $1.07 billion against analyst estimates of $1.10 billion, a 2.9% miss. The medical device company's non-GAAP profit of $1.15 per share beat consensus of $1.12 by 2.7%, while operating margin rose to 20.8% from 16.6% a year earlier. Management lowered full-year revenue guidance to $4.24 billion at the midpoint from $4.30 billion, a 1.5% decrease, and cut full-year Adjusted EPS guidance to $4.53 at the midpoint, a 1.9% decrease. CEO Albert White attributed the shortfall to proactive U.S. channel inventory reductions in the vision segment and muted performance in China, and said the company concluded a strategic review by deciding to retain CooperSurgical after a disconnect between internal valuations and market offers. CFO Brian Andrews cautioned that near-term margin pressure is likely as commercial investments ramp up alongside foreign exchange and tariff headwinds, though CooperCompanies generated record free cash flow and repurchased $339 million in shares this quarter, with the board approving an additional $1 billion for buybacks.
CooperCompanies Shares Fall 13.9% on Weak Q2, CooperSurgical Retention
CooperCompanies shares fell 13.9% after the medical device company reported weak second-quarter results and decided to retain its CooperSurgical business. Revenue came in at $1.07 billion, flat year-over-year and below analyst estimates of $1.10 billion, while organic revenue grew just 1%; adjusted earnings of $1.15 per share edged past the $1.12 consensus as operating margins expanded to 20.8% from 16.6% a year ago. Chief Executive Officer Al White said proactive U.S. channel inventory reductions at CooperVision weighed heavily on the top line and will continue to be a drag into the next quarter, prompting management to lower full-year revenue guidance to a midpoint of $4.24 billion from $4.30 billion and cut its full-year adjusted EPS outlook to $4.53 at the midpoint. The company also concluded a strategic review initiated in December 2025, with its board unanimously deciding to retain the CooperSurgical business after assessing acquisition proposals, citing valuation disconnects linked to incoming non-hormonal IUD competition and recent litigation settlements, and expanded its share repurchase authorization to $3 billion. William Blair downgraded CooperCompanies to Market Perform from Outperform following the report.
CooperCompanies Hits 52-Week Low After Cutting Full-Year Guidance
CooperCompanies shares plunged to a 52-week low of $51.08 on Thursday, down nearly 20% from Wednesday's close, after the vision care company lowered its full-year revenue and EPS guidance. Both fiscal 2026 guidance ranges now sit below consensus figures. The company also decided after a strategic review not to sell its women's health-centered CooperSurgical division, a move BNP Paribas analyst Navann Ty said may have contributed to the share decline. Ty added that CooperSurgical's flat organic growth in FY26 Q3 was another setback relative to competitors' operating performance. Cooper shares were down about 14% in Thursday afternoon trading.
CooperCompanies Concludes Strategic Review, Keeps CooperSurgical After Bids Fall Short
CooperCompanies reported third-quarter fiscal 2026 revenue of $1.066 billion, up about 1% on both a reported and organic basis, and concluded its strategic review by deciding to retain CooperSurgical after offers failed to reflect the unit's full value. The Board unanimously determined shareholders are better served by continued ownership than by a transaction at this time, citing temporary factors including a competitive entrant in the non-hormonal IUD market and the impact of the fertility litigation settlement. CooperVision revenue was $717 million, essentially flat year-over-year, as the company proactively reduced U.S. channel inventory, a move that will also weigh on the fourth quarter; underlying U.S. consumption still grew at a mid-single-digit rate. CooperSurgical revenue was $349 million, up 3% organically, with fertility up 5% to $141 million and office and surgical up 2% to $208 million. Non-GAAP EPS rose 4% to $1.15, marking the 11th consecutive quarter above consensus, and free cash flow of $273 million was the highest quarterly figure in Cooper's history; the company repurchased $339 million of shares in the quarter and the Board approved a $1 billion increase to its repurchase authorization, bringing remaining capacity to approximately $1.5 billion. For the fourth quarter, CooperCompanies guided to consolidated revenue of $1.057 billion to $1.08 billion, or 0% to 2% organic growth, and non-GAAP EPS of $1.05 to $1.09, with CooperVision revenue of $692 million to $706 million and CooperSurgical revenue of $364 million to $374 million.
Neogen Plans 50% R&D Increase as Petrifilm Manufacturing Moves In-House
Neogen Corporation is raising fiscal 2027 research and development spending by about 50% as it expands its food and animal safety pipeline and brings Petrifilm manufacturing in-house at its Lansing facility. The company expects to complete validation of the first Petrifilm SKU by the end of August 2026, with sellable production and a multi-quarter manufacturing transition beginning in November 2026, and it plans at least two Petrifilm SKU launches annually with at least five candidates identified. Neogen's Animal Safety business entered fiscal 2027 with most third-party supplier issues resolved, after fourth-quarter fiscal 2026 revenues fell 8.2% year over year while core revenues rose 0.5% and sales increased more than 7% sequentially. Neogen ended fiscal 2026 with $185.5 million in cash against about $800 million in debt, and plans to use roughly $140 million of expected net Genomics proceeds primarily for debt reduction. Over the past 30 days, the Zacks Consensus Estimate for Neogen's fiscal 2027 earnings has risen 3.3% to 31 cents, while the consensus mark for fiscal 2027 revenues is pegged at $883.2 million, suggesting a 1.5% rise from the prior year.
AeroVironment Jumps 6% on Record FQ1 Revenue, Cooper Companies Sinks 16%
AeroVironment shares jumped 6% after the defense contractor reported record FQ1 revenue of $480.5M, up 6% year over year and $24.5M above consensus, while adjusted EPS of $0.59 more than doubled the $0.25 estimate. Autonomous Systems revenue climbed 21% to $346M, led by a 71% increase in uncrewed aircraft systems sales to $120M, while Space, Cyber, and Directed Energy revenue fell 21% to $134.5M. Gross margin expanded to 26% from 21%, though adjusted EBITDA declined to $53.4M from $56.6M, and the company maintained its FY2027 revenue outlook of $2.125B-$2.225B and adjusted EPS guidance of $3.02-$3.34, both midpoints below consensus. The Cooper Companies tumbled 16% after its board decided to retain CooperSurgical following a strategic review, citing a valuation disconnect, and cut its FY2026 revenue guidance to $4.229B-$4.252B from $4.285B-$4.321B, below the $4.31B consensus, while lowering non-GAAP EPS guidance to $4.51-$4.55 from $4.58-$4.66 and raising its share repurchase authorization to $3B from $2B. American Eagle Outfitters plunged 11% despite beating Q2 expectations, with sales rising 9.4% year over year and profit up 34% to $0.79 per share, a result that included nearly $200M in tariff refunds, while the namesake brand's comparable sales declined 1%, partly offset by a 19% increase at Aerie and OFFLINE. The retailer expects Q3 operating income of $110M-$115M with mid-to-high-single-digit comparable sales growth, and raised its FY2026 operating income guidance to $540M-$550M from $390M-$410M.
Cooper Companies Guides Q4 EPS of $1.05-$1.09, Ends Strategic Review and Adds $1B to Buyback
The Cooper Companies guided to fourth-quarter non-GAAP earnings per share of $1.05 to $1.09 and said its board has concluded its strategic review, unanimously deciding to retain CooperSurgical rather than pursue a transaction. For the quarter, the company expects consolidated revenue of $1.057 billion to $1.08 billion, organic growth of 0% to 2%, with CooperVision revenue of $692 million to $706 million, down 2% to flat organically, and CooperSurgical revenue of $364 million to $374 million, up 4% to 6% organically. In its fiscal third quarter, consolidated revenue was $1.066 billion, up about 1% on both a reported and organic basis, non-GAAP EPS rose 4% to $1.15, and free cash flow reached a record $273 million. The quarter included a discrete tax benefit of approximately $307 million after the favorable completion of HMRC's examination of the fiscal 2021 transfer of intellectual property and related assets to the U.K., and the board approved a $1 billion increase to the share repurchase authorization, bringing remaining capacity to approximately $1.5 billion. CooperVision's results were weighed down by a proactive reduction of U.S. channel inventory that management said is about halfway complete and will continue to affect the fourth quarter, while the company flagged greater commercial investments, additional FX headwinds and lower tariff refunds as pressures on fourth-quarter margins.
Cooper Companies Q3 Revenue Misses Estimates, EPS Beats
The Cooper Companies reported $1.07 billion in revenue for the quarter ended July 2026, a 0.6% increase year-over-year, missing the Zacks Consensus Estimate of $1.1 billion by 2.97%. EPS came in at $1.15, beating the consensus of $1.11 by 3.6% and up from $1.10 a year ago. Among key segments, the CVI category generated $717 million, down 0.2% from last year and below the $742.19 million estimate, while the CSI category brought in $349.2 million, up 2.1% and slightly under the $356.69 million forecast. Geographically, Americas revenue fell 1.5% to $281.6 million, Asia Pacific dropped 10.2% to $126 million, and EMEA rose 5.9% to $309.4 million. Shares have declined 11.9% over the past month, and the stock carries a Zacks Rank #4 (Sell).
The Cooper Companies reported quarterly earnings of $1.15 per share, surpassing the Zacks Consensus Estimate of $1.11 per share, and up from $1.10 per share a year ago. This marks an earnings surprise of 3.60%, and the company has beaten consensus EPS estimates in each of the last four quarters. However, revenues of $1.07 billion for the quarter ended July 2026 missed the Zacks Consensus Estimate by 2.97%, though they were slightly above the year-ago figure of $1.06 billion. The company's shares have fallen 17.4% since the start of the year, compared to a 12.1% gain for the S&P 500. Looking ahead, the consensus EPS estimate for the coming quarter is $1.20 on revenues of $1.1 billion, and for the current fiscal year it is $4.63 on revenues of $4.31 billion. The stock currently carries a Zacks Rank #4 (Sell), indicating expected underperformance in the near term.
CooperCompanies Plunges on Weak Guidance, Strategic Review Conclusion
CooperCompanies shares plunged 15% in after-hours trading Wednesday after the medical device company reported third-quarter results that missed revenue expectations and issued fourth-quarter and full-year guidance significantly below analyst estimates. The company reported adjusted earnings per share of $1.15 for the fiscal third quarter ended July 31, 2026, beating the analyst consensus of $1.12 by $0.03, but revenue of $1.07 billion fell short of the $1.1 billion estimate, though it represented a 1% increase year-over-year. The company also announced it would retain CooperSurgical after completing its strategic review process, concluding that offers received were not in shareholders' best interest. For the fourth quarter, the company expects adjusted EPS of $1.05 to $1.09, with the midpoint of $1.07 well below the consensus of $1.19, and revenue projected at $1.057 billion to $1.080 billion, trailing the $1.11 billion estimate. Full-year guidance calls for adjusted EPS of $4.51 to $4.55, below the $4.63 consensus, and revenue between $4.229 billion and $4.252 billion, under the $4.31 billion estimate. CooperVision revenue was flat at $717.0 million, while CooperSurgical revenue grew 2% to $349.2 million. The company generated free cash flow of $273.0 million, up 66% year-over-year, repurchased $339.1 million of stock, and expanded its share repurchase authorization from $2 billion to $3 billion.
CooperCompanies reported Q2 CY2026 sales of $1.07 billion, flat year on year and below analyst estimates of $1.10 billion, causing its stock to drop 16.8% to $52.91. The company's adjusted EPS of $1.15 beat expectations by 2.7%, but it lowered its full-year revenue guidance to $4.24 billion at the midpoint, a 1.5% cut, and reduced its adjusted EPS guidance to $4.53, a 1.9% decrease. Organic revenue rose only 1% year on year, missing estimates, while operating margin improved to 20.8% from 16.6% a year ago. CEO Al White noted that reduced U.S. channel inventory at CooperVision weighed on results and will continue to impact Q4, but highlighted record free cash flow and solid fertility growth at CooperSurgical.
Cooper Companies Q3 EPS Beats, Revenue Misses; Shares Fall
The Cooper Companies reported fiscal third-quarter non-GAAP EPS of $1.15, beating estimates by $0.03, while revenue of $1.07 billion, up 0.9% year over year, missed by $30 million. The company also issued weaker-than-expected guidance for the fiscal fourth quarter and full year 2026, with Q4 revenue projected between $1.057 billion and $1.080 billion versus a consensus of $1.11 billion, and Q4 non-GAAP EPS of $1.05 to $1.09 versus a consensus of $1.19. For the full fiscal year, revenue is expected between $4.229 billion and $4.252 billion versus a consensus of $4.31 billion, and non-GAAP EPS of $4.51 to $4.55 versus a consensus of $4.63. The company reaffirmed its long-term free cash flow objective exceeding $2.2 billion for fiscal years 2026 through 2028. Shares fell 6.22% in response.
CooperCompanies Reports Q3 2026 Results, Boosts Buyback to $3 Billion
CooperCompanies announced fiscal third quarter 2026 results, with revenue rising 1% year-over-year to $1.066 billion and non-GAAP diluted EPS up 4% to $1.15, while GAAP EPS surged to $2.24 on a $307.2 million tax benefit. The company completed its strategic review, repurchased $339.1 million of stock, and expanded its buyback authorization from $2 billion to $3 billion, leaving about $1.5 billion available. Free cash flow jumped 66% to $273.0 million. CooperVision revenue was flat at $717.0 million, while CooperSurgical grew 2% to $349.2 million. For fiscal 2026, the company guides total revenue of $4.229-$4.252 billion and non-GAAP EPS of $4.51-$4.55, reaffirming a long-term free cash flow objective exceeding $2.2 billion for fiscal years 2026 through 2028.
CooperCompanies Completes Strategic Review, Boosts Buyback to $3 Billion
CooperCompanies has completed its strategic review, with the board unanimously deciding to retain CooperSurgical and expanding its share repurchase authorization from $2 billion to $3 billion. The company repurchased $445 million of shares this fiscal year and will prioritize investments in CooperVision while CooperSurgical focuses on organic growth and operational improvements. The board added two new independent directors and remains open to other value-creating alternatives. CooperCompanies also announced its Q3 2026 earnings results in a separate release.
TOG Confirms Trade War Has No Impact, Orders Continue to Flow
Thai Optical Group Public Company Limited (TOG) has confirmed that the trade war between the United States and Canada does not directly affect its business, as it has production bases in Thailand and orders from key markets continue to flow in steadily. The company remains focused on maintaining its market base in the U.S. and Canada, while seeking opportunities to expand into new markets in the Middle East, particularly Lebanon. However, the company has restored approximately 90% of its production capacity following the building fire, with the remaining 10% expected to be gradually restored once the building renovation is completed.
Cooper Companies to Report Q3 Earnings Wednesday After Close
The Cooper Companies is scheduled to announce its Q3 earnings results on Wednesday, September 9th, after market close. The consensus EPS estimate is $1.12, up 1.8% year over year, while the consensus revenue estimate is $1.1 billion, up 3.8% year over year. Over the last two years, the company has beaten EPS estimates 100% of the time and revenue estimates 38% of the time. In the past three months, EPS estimates have seen zero upward revisions and 13 downward, while revenue estimates have seen zero upward and 12 downward.
Dentsply Sirona Inc. reported second-quarter adjusted earnings of 52 cents per share, beating the Zacks Consensus Estimate of 36 cents by 44.4%, while revenues of $898 million topped expectations by 1.6%, despite a 4.1% year-over-year decline as reported and a 6.3% drop at constant currency. The company maintained its 2026 net sales outlook of $3.5 billion to $3.6 billion and adjusted earnings guidance of $1.40-$1.50 per share, excluding tariff refund benefits. Wellspect Healthcare was the bright spot, with revenues up 7.1% to $86 million, while Connected Technology Solutions fell 1.5%, Essential Dental Solutions declined 2.7%, and Orthodontic and Implant Solutions dropped 13.2%. Adjusted gross margin improved 50 basis points to 56.4%, and adjusted EBITDA margin rose 20 basis points to 21.3%, but adjusted operating margin contracted 240 basis points to 15.8% due to lower volumes, unfavorable mix, tariff costs, and higher expenses. Free cash flow increased to $55 million from $16 million a year earlier, though cash and equivalents fell to $239 million from $326 million at year-end 2025, with net debt-to-EBITDA at 3.2.
MiniMed Raises Fiscal 2027 Revenue Outlook After Strong Q1
MiniMed reported fiscal first-quarter revenue of $843 million, up 15.8% organically, and raised its full-year organic revenue growth outlook to approximately 10.5% from 10%. The company, which became a stand-alone public company in early March after its IPO, saw U.S. revenue grow 13.1% and international revenue rise 16.9%, with the extra week in the fiscal calendar contributing 4 to 6 points to growth. Adjusted EBITDA was $83 million, a margin of 9.9%, including a 230-basis-point impact from accelerated investments and a nonoperational FX charge. CEO Que Dallara highlighted the successful launch of the MiniMed Flex pump, which drove U.S. new pump sales up over 20%, and announced that the MiniMed Fit patch pump has been submitted to the FDA ahead of schedule, with a full U.S. launch expected by summer 2027. The company also completed enrollment in the U.S. pivotal trial for its Vivera fully closed-loop algorithm, with a launch expected in the second half of calendar 2027, and received IDE approval for a next-generation extended wear sensor.
CooperCompanies Earnings Preview: Revenue Growth Expected to Slow
CooperCompanies is set to report earnings after market close on Wednesday, with analysts expecting revenue to grow 3.5% year on year, a slowdown from the 5.7% increase recorded in the same quarter last year. The medical device company beat analysts' revenue expectations last quarter, reporting revenues of $1.08 billion, up 7.9% year on year, and also exceeded EPS estimates. Analysts have generally reconfirmed their estimates over the past 30 days, though CooperCompanies has missed Wall Street's revenue estimates multiple times in the last two years. Peers Baxter and Neogen have already reported strong results, with Baxter beating revenue expectations by 6% and Neogen topping estimates by 6%, leading to share price gains of 5.6% and 28.1%, respectively. CooperCompanies shares are down 8.4% over the past month, trading at $70.30, with an average analyst price target of $81.50.
Dentsply Sirona Reaffirms 2026 Outlook After Q2 Profit Recovery
Dentsply Sirona reported second-quarter 2026 results showing a 4.1% year-over-year net sales decline but a return to net income, with higher margins and stronger cash generation, and confirmed it will present at the Baird 2026 Global Healthcare Conference on September 15, 2026. Management reiterated full-year 2026 guidance of US$3.5 billion to US$3.6 billion in net sales and adjusted EPS of US$1.40 to US$1.50, despite the sales drop, highlighting a sharper focus on efficiency and margin quality. The company's narrative projects US$3.8 billion revenue and US$189.7 million earnings by 2029, requiring a US$817.7 million earnings increase from -US$628.0 million today, and yields a fair value of US$13.40, a 17% upside to its current price. However, cautious analysts assume roughly flat revenue near US$3.7 billion and only about US$73.7 million of earnings, sketching a far more constrained recovery path that this latest profit rebound might or might not meaningfully shift.
FIGS, Inc. reported that its international revenue surged 67% year over year to $37.9 million in the second quarter of 2026, accelerating from 49.9% growth in the first quarter. International sales now account for approximately 19% of total revenues, with existing comparable markets contributing more than 50 percentage points to the growth. Management highlighted exceptional performance in Europe, Latin America, and Mexico, along with improvements in Canada, Australia, and the Middle East. The company expanded its reach to 85 international markets by July 2026, adding 27 markets since year-end 2025, and its institutional business is extending overseas, including a recent partnership with Bupa Dental Care to outfit nearly 400 dental centers in the United Kingdom. Following the strong quarter, FIGS raised its 2026 revenue growth expectation to approximately 20%, up from a prior range of 14% to 16%.
Medtronic, MiniMed, NIO, Apple Move on Earnings and CEO Change
Medtronic plc's shares rose 1.5% after reporting first-quarter fiscal 2027 revenues of $9,756 million, surpassing the Zacks Consensus Estimate of $9,470.48 million. MiniMed Group Inc. shares jumped 10.7% after posting first-quarter fiscal 2027 revenues of $843 million, beating the estimate of $828 million. NIO Inc. shares tumbled 4% after reporting second-quarter fiscal 2026 revenues of $4,736.39 million, missing the estimate of $4,780.55 million. Apple Inc. shares gained 2.6% after John Ternus, its former senior vice president of hardware engineering, became the new CEO, succeeding Tim Cook after 15 years.
MiniMed Soars on Revenue Growth and Price Target Hike
MiniMed Group's shares jumped 10.66 percent to close at $22.42 after the company reported strong first-quarter revenue growth and received a price target upgrade from BTIG, which raised its target to $28 from $25 while maintaining a buy rating. The company's revenue for the first quarter of fiscal year 2027 grew 16.6 percent to $843 million from $723 million a year earlier, beating consensus estimates of $826.8 million, and it narrowed its attributable net loss to zero from a $19 million loss in the prior-year period. Encouraged by the results, MiniMed raised its full-year organic revenue growth guidance to 10.5 percent from 10 percent, while reaffirming its adjusted EBITDA margin at 16 percent. However, hedge fund conviction weakened in the second quarter, as combined holdings fell 18 percent to $237.55 million from $290.58 million, despite the number of hedge fund holders increasing to 26 from 22.
MiniMed Group Raises Fiscal 2027 Outlook After Strong Q1
MiniMed Group reported fiscal 2027 first-quarter revenue of $843 million, up 15.8% organically, and raised its full-year organic growth forecast to approximately 10.5%. Excluding the benefit of an extra fiscal week, growth was in the low double digits, compared with 8.7% in the prior quarter. U.S. revenue rose 13.1%, driven by the MiniMed Flex pump launch, which contributed to a more than 20% increase in new pumps sold and a 24% rise in new prescribers. International organic revenue grew 16.9%, with Western Europe up in the high teens. Adjusted EBITDA was $83 million, a margin of 9.9%, including impacts from accelerated investments and a foreign-exchange charge; excluding those, the margin would have been 12.2%. The company reaffirmed its 16% adjusted EBITDA margin target for the year and provided pipeline updates, including the Fit patch pump and Vivera closed-loop algorithm.
Utah Medical Products announced that its Femcare unit has acquired all ordinary shares of U.K.-based Orion Medical Supplies for £3.6 million in cash. The deal is expected to add approximately $6 million to annual sales, with potential for further geographic expansion. The acquisition is expected to benefit margins by leveraging Femcare's existing infrastructure, and the company plans to integrate Orion's operations into Femcare's existing Romsey facilities. Shares rose 1.35% following the announcement.
TELA Bio COO/CFO Roberto Cuca Steps Down Amid Cost Cuts
TELA Bio announced that Roberto Cuca, its Chief Operating Officer and Chief Financial Officer, will step down from his role. The company also revealed a headcount reduction of approximately 20% as part of a strategic cost reduction initiative. TELA Bio expects to incur a one-time restructuring charge of about $1.5 million in the third quarter of 2026, primarily related to severance and other employee-related costs.
Zhengchuan Shares' 2026 Interim Report Shows Net Profit Down 12.79% Year-on-Year
Zhengchuan Shares released its 2026 interim report. Total operating revenue was 381 million yuan, and net profit attributable to the parent company was 12.2866 million yuan, down 12.79% from the same period last year. Net cash inflow from operating activities was 79.3259 million yuan. The asset-liability ratio was 37.64%, gross margin was 17.35%, return on equity was 1.03%, and diluted earnings per share was 0.08 yuan. The company had 21,600 shareholders, and the top ten shareholders held 71.87% of total share capital.
Nanwei Shares' 2026 Interim Net Loss Widens to 17.79 Million Yuan
Nanwei Shares released its 2026 interim report, showing total operating revenue of 271 million yuan, down 11.51 percent year on year, and a net loss attributable to the parent company of 17.79 million yuan, with the loss widening by 4.82 million yuan compared with the same period last year. Net cash inflow from operating activities was 30.12 million yuan, down 14.42 percent year on year. The company's asset-liability ratio rose to 81.31 percent, gross margin was 10.35 percent, return on equity was negative 11.16 percent, and diluted earnings per share was negative 0.06 yuan. The number of shareholders was 11,700, and the top ten shareholders held 56.95 percent of the total share capital.
Nanwei Shares H1 Revenue Falls 11.5%, Loss Widens to 17.79 Million Yuan
Nanwei Shares released its 2026 half-year report on August 30. First-half operating revenue was 271 million yuan, down 11.5% year on year. Net profit attributable to the parent swung from a loss of 12.97 million yuan in the same period last year to a loss of 17.79 million yuan, while net profit attributable to the parent excluding non-recurring items widened from a loss of 15.4 million yuan to a loss of 18.61 million yuan. Second-quarter revenue was 116 million yuan, down 14.4% year on year, and the net loss attributable to the parent was 12.7 million yuan, wider than the 5.05 million yuan loss a year earlier. As of the end of the second quarter, total assets stood at 875 million yuan, down 5.7% from the end of the previous year, and net assets attributable to the parent were 159 million yuan, down 10.04%. The company said the revenue decline was mainly due to market factors that reduced revenue across product lines, the profit decline was caused by intense market competition and lower revenue, and the decrease in operating cash flow was due to a reduction in other cash received from operating activities. During the reporting period, research and development spending was 10.96 million yuan, aimed at consolidating its technical advantages in transdermal products.
Zhengchuan Shares first-half 2026 net profit 12.2866 million yuan
Zhengchuan Shares disclosed its 2026 semi-annual report on August 29. In the first half, it achieved total operating revenue of 381 million yuan, up 17.58 percent year on year. Net profit attributable to the parent company was 12.2866 million yuan, down 12.79 percent year on year. Non-recurring net profit was 7.0809 million yuan, down 30.65 percent year on year. Net cash flow from operating activities was 79.3259 million yuan, up 33.63 percent year on year. Basic earnings per share were 0.08 yuan, and the weighted average return on equity was 1.03 percent. The company specialises in the research, development, production and sale of pharmaceutical packaging materials such as medicinal glass tubing bottles.
Zhengchuan Shares' first-half net profit attributable to parent falls 12.8% year-on-year
Zhengchuan Shares released its 2026 interim report on August 28. First-half operating revenue was 381 million yuan, up 17.6% year-on-year, but net profit attributable to the parent was 12.29 million yuan, down 12.8% year-on-year, and net profit attributable to the parent after deducting non-recurring items was 7.08 million yuan, down 30.7% year-on-year. In the second quarter, operating revenue was 172 million yuan, up 6.1% year-on-year, net profit attributable to the parent was 5.46 million yuan, up 72.0% year-on-year, and net profit attributable to the parent after deducting non-recurring items was 1.75 million yuan, up 48.4% year-on-year. The company said the profit decline was mainly due to lower selling prices for some products and rising raw material procurement costs, including year-on-year increases in prices of raw materials such as borax, aluminum strip, and rubber stoppers, as well as higher natural gas costs. In addition, intensifying industry homogenization and continued price-cut pressure transmitted by centralized procurement policies meant that although sales volume and operating revenue grew year-on-year, profitability came under phased pressure.
Minsheng Health Releases 2026 Interim Report with Net Profit of 83.3943 Million Yuan
Minsheng Health released its 2026 interim report on August 28, 2026. During the reporting period, the company achieved total operating revenue of 535 million yuan and net profit attributable to the parent company of 83.3943 million yuan. Net cash inflow from operating activities was 137 million yuan, a decrease of 5.2026 million yuan compared with the same period last year, down 3.67 percent year on year. The company's asset-liability ratio was 17.68 percent, up 2.13 percentage points from the previous quarter and up 3.00 percentage points from the same period last year. Gross margin was 55.17 percent, down 2.61 percentage points from the previous quarter. Return on equity was 5.17 percent, down 0.05 percentage points from the same period last year. Diluted earnings per share were 0.23 yuan. Total asset turnover was 0.26 times, and inventory turnover was 2.79 times. The number of shareholders was 17,600, and the top ten shareholders held 255 million shares, accounting for 71.59 percent of total share capital.
Minsheng Health's first-half net profit attributable to parent was 83.39 million yuan, up 1.2% year on year
Minsheng Health released its 2026 half-year report. Net profit attributable to the parent in the first half was 83.39 million yuan, up 1.2% year on year. Operating revenue was 535 million yuan, up 15.8% year on year. Net profit attributable to the parent after deducting non-recurring items was 86.23 million yuan, up 8.7% year on year. Net operating cash flow was 137 million yuan, down 3.7% year on year. Earnings per share were 0.2339 yuan. In the second quarter, operating revenue was 218 million yuan, up 14.1% year on year, and net profit attributable to the parent was 20.62 million yuan, up 4.6% year on year. As of the end of the second quarter, total assets were 2.104 billion yuan, up 4.3% from the end of the previous year, and net assets attributable to the parent were 1.612 billion yuan, up 0.9% from the end of the previous year. The company's main product, 21 Gold Vita multivitamin tablets, has performed well in the market, and the company is expanding its business through distributors and online channels.